Search

Displaying results 4841 - 4850 of 10000 in total
  1. Drug

    Fleroxacin

    go.drugbank.com/drugs/DB04576
    Experimental

    Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.[A39048]

    Categories: Topoisomerase II Inhibitors
  2. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.

  3. Drug

    LX201

    go.drugbank.com/drugs/DB04943
    Investigational

    LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. … The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc.

  4. Drug

    Ertiprotafib

    go.drugbank.com/drugs/DB06521
    Experimental

    In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test. … Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes.

  5. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor.

  6. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  7. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia.

  8. Drug

    1alpha,24S-Dihydroxyvitamin D2

    go.drugbank.com/drugs/DB06117
    Experimental

    LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. … It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.

  9. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. … It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

  10. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.